Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBiome Tech Regulatory News (BIOM)

Share Price Information for Biome Tech (BIOM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 85.00
Bid: 70.00
Ask: 100.00
Change: 0.00 (0.00%)
Spread: 30.00 (42.857%)
Open: 85.00
High: 85.00
Low: 85.00
Prev. Close: 85.00
BIOM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

28 Jan 2021 07:00

RNS Number : 1233N
Biome Technologies PLC
28 January 2021
 

This announcement contains inside information for the purposes of Regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310.

28 January 2021

Biome Technologies plc

("Biome", "the Company" or "the Group")

Trading Update

Biome Technologies plc, a leading bioplastics and radio frequency technology business, today provides an unaudited pre-close trading update for the financial year ended 31 December 2020.

Group revenues for the year ended 31 December 2020 were broadly in line with market expectations at £5.7m (2019: £6.9m) following strong annual revenue growth of 65% in the Bioplastics division.

Cash balances at the year-end were £1.7m, following the net £1m equity fundraising announced in September 2020 (30 September 2020: £0.9m).

The Board anticipates that, subject to completion of the audit process, the Group will generate a loss before interest, taxation, depreciation, amortisation and share option charges for the year ended 31 December 2020, which will be in line with current market expectations.

The Group's preliminary results for the year ended 31 December 2020 are scheduled to be published on 25 March 2021.

Bioplastics Division

The division's revenues for the full year to 31 December 2020 were £4.9m, 65% ahead of full year 2019 revenues of £3.0m. Revenues in Q4 were £1.2m, 20% ahead of the prior year comparative quarter (Q4 2019: £1.0m), but lower than the preceding quarter (Q3 2020: £1.6m) as indicated in the Company's Trading Update on 29 October 2020.

The Board expects significant revenue growth from this division in 2021, with further product implementations in progress with both existing and new customers.

Stanelco RF Technologies Division

Revenues for the division for the full year to 31 December 2020 were £0.8m, £0.3m being generated in Q4, slightly ahead of the preceding quarter's revenue of £0.2m. This subdued revenue level reflects the on-going over-capacity in the division's main fibre-optic cable market.

The division has substantially reduced its overheads in the last year and is focussing on growing its presence in its other markets, resulting in a growing pipeline of opportunities. The Board is continuing to monitor the division's trading outlook carefully.

Group Performance

Throughout the Covid-19 pandemic, the Group has continued its manufacturing and development operations in conformance with Government advice, ensuring the safety of staff. The Group continues to make selective use of the UK Government's Job Retention Scheme for staff within the Stanelco RF Technologies division.

Whilst the Board anticipates the Group's loss before interest, taxation, depreciation, amortisation and share option charges for the year to be in line with current market expectations, the Statutory Underlying Loss is likely to be below market expectations due to a larger than anticipated non-cash share-based payment charge.

The Group's cash position as at 31 December 2020 was £1.7m (30 September 2020: £0.9m). In Q4, the cash position was increased by the equity fundraising announced in September 2020 of £1.0m (net of costs), to support the continuing growth of the Bioplastics division. The remainder of the change in the Group's cash position was a result of trading performance in the quarter. The Group has no debt.

Group Outlook

Whilst the longer-term outlook for the Stanelco RF Technologies division is slightly more encouraging than in 2020, the Board expects that headwinds will continue in the short term.

The underlying trends and technical innovation that have driven growth in the Bioplastics division are anticipated to continue as consumers increasingly demand that plastic waste is managed in a better manner. The projects that underpin the division's expected growth in 2021 are proceeding well.

The Board remains confident of meeting market expectations in 2021.

- Ends -

For further information please contact: Biome Technologies plc

Paul Mines, Chief Executive Officer

Rob Smith, Chief Financial Officer

info@biometechnologiesplc.co.uk

Tel: +44 (0) 2380 867 100

www.biometechnologiesplc.com

 

Allenby Capital

David Hart/Alex Brearley (Nominated Adviser)

Kelly Gardiner (Sales and Corporate Broking)

Tel: +44 (0) 20 3328 5656

www.allenbycapital.com

 

About Biome

 

Biome Technologies plc is an AIM listed, growth-orientated, commercially driven technology group. Our strategy is founded on building market-leading positions based on patented technology and serving international customers in valuable market sectors. We have chosen to do this by developing products in application areas where the value-added pricing can be justified and are not reliant on government legislation. These products are driven by customer requirements and are compatible with existing manufacturing processes. They are market rather than technology-led.

 

The Group comprises two divisions, Biome Bioplastics Limited and Stanelco RF Technologies Limited.

 

Biome Bioplastics is a leading developer of highly-functional, bio-based and biodegradable plastics. The company's mission is to produce bioplastics that challenge the dominance of oil-based polymers.

 

Stanelco RF Technologies designs, builds and services advanced radio frequency (RF) systems. Dielectric and induction heating products are at the core of a product offering that ranges from portable sealing devices to large furnaces for the fibre optics markets.

 

www.biometechnologiesplc.com

www.biomebioplastics.com and www.thinkbioplastic.com 

www.stanelcorftechnologies.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTDKOBPOBKDFDB
Date   Source Headline
31st Oct 200611:54 amRNSNotifiable Interest
17th Oct 20065:54 pmRNSNotifiable Interest
17th Oct 200610:44 amRNSNotifiable Interest
16th Oct 20063:17 pmRNSNotifiable Interest
12th Oct 200612:35 pmRNSDoc re. Posting of Prospectus
11th Oct 20061:09 pmRNSNotifiable Interest
9th Oct 200611:13 amRNSProposed Placing & Open Offer
5th Oct 200610:25 amRNSFinancing Update
3rd Oct 200612:56 pmRNSStatement re. Press Comment
2nd Oct 20064:41 pmRNSSecond Price Monitoring Extn
2nd Oct 20064:35 pmRNSPrice Monitoring Extension
8th Sep 20067:01 amRNSTrading Statement
17th Aug 20067:44 amRNSTrading Statement
16th Aug 20065:52 pmRNSAdditional Listing - AMEND
14th Aug 200611:55 amRNSAdditional Listing
10th Aug 200612:25 pmRNSRe Contract
14th Jul 20067:56 amRNSInterim Results - Replacement
14th Jul 20067:00 amRNSInterim Results
2nd Jun 200611:26 amRNSNew Ord Share Placing-Amendmt
2nd Jun 20068:45 amRNSNew Ordinary Share Placing
25th May 20067:02 amRNSWrap 100 FDA approval
16th May 200610:43 amRNSAdditional Listing
15th May 20067:01 amRNSAppointment of Adviser
3rd May 20061:05 pmRNSNotifiable Interest
2nd May 20064:58 pmRNSResult of AGM
2nd May 20062:00 pmRNSAGM Statement
10th Apr 20063:12 pmRNSAnnual Report and Accounts
7th Apr 20062:46 pmRNSAdditional Listing
13th Mar 20067:02 amRNSDirectorate Change
28th Feb 20067:02 amRNSPreliminary Results
24th Feb 20067:02 amRNSCooperation with Wal-Mart
14th Feb 20069:07 amRNSAdditional Listing
14th Feb 20067:00 amRNSUS FDA approval for Starpol
9th Feb 200610:42 amRNSIsraCaps new licence terms
9th Feb 20067:02 amRNSRe: BioProgress plc
16th Dec 20057:01 amRNSFunding for R&D facility
16th Dec 20057:01 amRNSPre Close Update
14th Dec 20057:01 amRNSLandmark deal with Perseco
8th Dec 200510:25 amRNSShare Listing Application
30th Nov 20055:40 pmRNSDirectorate Change
28th Nov 20059:24 amRNSBoard Changes
8th Nov 20057:01 amRNSPatent sale process update
3rd Nov 20054:47 pmRNSExercise of Options
1st Nov 20057:02 amRNSChange of Adviser
12th Oct 20057:00 amRNSApproval of Starpol
3rd Oct 20057:00 amRNSPatent Disposal & Update
22nd Sep 20057:02 amRNSRe Agreement
12th Sep 20057:03 amRNSDevelopment of capsule
5th Sep 20057:03 amRNSRe: Completion
30th Aug 20053:30 pmRNSDoc re. Result of EGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.